Bezlotoxumab for prevention of <i>Clostridioides difficile</i> recurrence in patients with inflammatory bowel disease: a retrospective multicenter experience.

Ann Gastroenterol · 2026 · PMC12850694 · PMID 41612991

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the overall rate of rCDI was numerically higher in patients with IBD than those without IBD, the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Bezlotoxumab for prevention of &lt;i&gt;Clostridioides difficile&lt;/i&gt; recurrence in patients with inflammatory bowel disease: a retrospective multicenter experience.

The sentences

Bezlotoxumab for prevention of <i>Clostridioides difficile</i> recurrence in patients with inflammatory bowel disease: a retrospective multicenter experience.